plumbagin has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alwagdani, H; Kolta, MG; Mendonca, P; Messeha, SS; Soliman, KFA; Zarmouh, NO | 1 |
| Anilkumar, TV; Hemalatha, SK; Jose, J; Kumar, JM; Nadhan, R; Nair, RS; Sengodan, SK; Somasundaram, V; Srinivas, P | 1 |
2 other study(ies) available for plumbagin and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
The inhibitory effects of plumbagin on the NF-қB pathway and CCL2 release in racially different triple-negative breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Black or African American; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemokine CCL2; Female; Humans; Naphthoquinones; NF-kappa B; Paclitaxel; RNA, Messenger; Signal Transduction; Triple Negative Breast Neoplasms; Tumor Necrosis Factor-alpha; White People | 2018 |
Increased sensitivity of BRCA defective triple negative breast tumors to plumbagin through induction of DNA Double Strand Breaks (DSB).
Topics: Animals; Apoptosis; BRCA1 Protein; Cell Line, Tumor; DNA Breaks, Double-Stranded; Female; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Knockout; Naphthoquinones; Triple Negative Breast Neoplasms; Tumor Suppressor Proteins | 2016 |